EDX Medical Group (LSE:EDX) returned to shareholders for funding in August, only a few months after moving its shares to AIM. The company said the money would go towards one specific Business line. The question is why EDX chose to put fresh Capital behind employee health screening, and what its finances and recent announcements say about the strategy.

A Cambridge diagnostics business

EDX Medical describes itself as a developer of "innovative digital diagnostic products and services" focused on early disease detection and treatment. According to its annual report, it runs laboratory facilities in Cambridge and works across hereditary and genetic risk assessment, early disease detection and disease characterisation to guide therapy. Its activities include testing for bowel and testicular cancer, a pneumonia diagnostic developed with partners including the University of Cambridge and the UK Health Security Agency, and participation in the Scottish Prostate Cancer Initiative. The Scottish Prostate Cancer Initiative, according to the annual report, is a project to test 25,000 men, and EDX published an update on it on 27 August 2026. Jason Holt is chairman and Dr Mike Hudson is chief executive. The shares began trading on AIM on 13 May 2026, having previously been quoted on the Aquis market.

The fundraising and its purpose

On 24 August 2026, EDX announced a £2.7 million subscription for 19,378,563 new ordinary shares at 14p each, with warrants attached. The company stated that "the net proceeds of the Fundraising will be used to support the expansion of the Company's new employee health screening service." The shares were admitted on 28 August, taking the total in issue to 431,373,146.

That service was launched on 15 July 2026, and on 17 September EDX announced an employee health contract with the Arnold Clark Group. The sequence suggests the company sees corporate screening as a route to Recurring Revenue that can be scaled faster than its clinical product development. At the Annual General Meeting on 28 September 2026, all 13 resolutions were passed with very high support, and the company has announced an online investor presentation through Investor Meet Company.

Financial position

The Annual Report published on 3 September 2026 shows how early-stage the business remains. For the year to 31 March 2026, revenue rose to £330,541 from £122,608. However, the company recorded a gross loss of £146,650, compared with a Gross Profit of £29,443 a year earlier, and its loss before tax widened to £5,841,759 from £3,724,626. The loss per share was 1.50p. Cash at the year end was £2,915,765, and net Assets fell to £2,165,324.

Those figures indicate that EDX is spending well ahead of its income as it builds laboratory capacity and launches services. The August raise added to cash after the period end, but at the reported rate of losses the company is likely to need further revenue growth or capital over time. That is an inference from the published numbers rather than a company statement.

Risks and uncertainties

Diagnostics businesses face long sales cycles with the NHS and corporate customers, and early contracts may be small. Regulatory requirements will rise as EDX moves, as it plans, from laboratory assays towards regulated in vitro diagnostic devices. Further share placings could dilute existing holders, and the warrants attached to the August subscription represent potential future share issuance. Delivery on the Arnold Clark contract and new corporate wins will be important indicators.

Conclusion

EDX raised £2.7 million to expand employee health screening because, by its own account, that service is where it wants to direct new capital, and an early corporate contract has already followed. The annual results show rising but still modest revenue against widening losses, so commercial traction in screening is central to the company's next stage.